Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Oslo Bors  >  Photocure ASA    PHO   NO0010000045

PHOTOCURE ASA

(PHO)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Oslo Bors
12/02/2019 12/03/2019 12/04/2019 12/05/2019 12/06/2019 Date
86.5(c) 85.1(c) 101.4(c) 87.3(c) 88.2(c) Last
757 438 811 352 1 422 803 1 505 892 493 689 Volume
+6.79% -1.62% +19.15% -13.91% +1.03% Change
More quotes
Financials (NOK)
Sales 2019 237 M
EBIT 2019 3,14 M
Net income 2019 15,4 M
Finance 2019 125 M
Yield 2019 -
Sales 2020 299 M
EBIT 2020 59,2 M
Net income 2020 47,3 M
Finance 2020 168 M
Yield 2020 -
P/E ratio 2019 126x
P/E ratio 2020 40,9x
EV / Sales2019 7,58x
EV / Sales2020 5,87x
Capitalization 1 921 M
More Financials
Company
Photocure ASA is a Norway-based company active in the pharmaceutical industry. It operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities... 
Sector
Pharmaceuticals
Calendar
02/25Earnings Release
More about the company
Surperformance© ratings of Photocure ASA
Trading Rating : Investor Rating :
More Ratings
Latest news on PHOTOCURE ASA
12/06PHOTOCURE : to present at the DNB Nordic Healthcare Conference in Oslo
AQ
11/29PHOTOCURE : to present at Nordic-American Life Science Conference in New York
AQ
11/21PHOTOCURE : Financial calendar
AQ
11/18PHOTOCURE :  First trial demonstrating reduced recurrence after flexible Blue Li..
AQ
11/07PHOTOCURE ASA : Results for the third quarter of 2019
AQ
11/05PHOTOCURE : Cysview® reimbursement further improved from January 2020
AQ
10/30PHOTOCURE ASA : Invitation to third quarter 2019 results presentation and webcas..
AQ
10/28PHOTOCURE : New data from Hexvix® trials presented at the BLADDR 2019 congress
AQ
10/21PHOTOCURE : Hexvix® with Flexible Scopes in New Study presented at the SIU Congr..
PU
09/30PHOTOCURE : Hexvix® to be featured at the upcoming BLADDR 2019 congress
PU
09/19PHOTOCURE : to present at Norne Securities Vekst & Verdi Aksjeseminar in Vilnius
AQ
09/03PHOTOCURE : to present at the H.C. Wainwright 21st Annual Healthcare Conference ..
AQ
08/07PHOTOCURE ASA : Results for the second quarter and first half of 2019
AQ
07/31PHOTOCURE ASA : Invitation to second quarter and first half year 2019 results pr..
AQ
07/30PHOTOCURE : to present at European Biotech Investor Day 2019 in New York
AQ
More news
News in other languages on PHOTOCURE ASA
2018PHOTOCURE ASA : Veröffentlichung des Quartalsergebnisses
2018PHOTOCURE ASA : publication des résultats trimestriels
2017PHOTOCURE ASA : publication des résultats semestriels
2017PHOTOCURE ASA : Veröffentlichung des Halbjahresergebnisses
2017PHOTOCURE ASA : publication des résultats trimestriels
More news
Analyst Recommendations on PHOTOCURE ASA
More recommendations
Sector news : Pharmaceuticals - NEC
12/06BRISTOL MYERS SQUIBB : Bluebird Bio Release Results of KarMMa Phase 2 Study
DJ
12/06JOHNSON & JOHNSON : Janssen Says Investigational Treatment for Myeloma Gets FDA ..
DJ
12/06AMGEN : Says FDA Approves Avsola for Same Indications as Remicade
DJ
12/06BRISTOL-MYERS, ACCELERON : FDA Drops Planned Panel Review of Reblozyl
DJ
12/06BAYER : to Hold Settlement Talks for Some Glyphosate Suits --Reuters
DJ
More sector news : Pharmaceuticals - NEC
Chart PHOTOCURE ASA
Duration : Period :
Photocure ASA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHOTOCURE ASA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus SELL
Number of Analysts 2
Average target price 70,00  NOK
Last Close Price 88,20  NOK
Spread / Highest target -20,6%
Spread / Average Target -20,6%
Spread / Lowest Target -20,6%
EPS Revisions
Managers
NameTitle
Daniel Schneider President & Chief Executive Officer
Jan Hendrik Egberts Chairman
Gry Stensrud VP-Technical Development & Operations
Erik Dahl Chief Financial Officer
Inger Ferner Heglund Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PHOTOCURE ASA83.75%210
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.10%263 079
MERCK AND COMPANY16.28%226 211
PFIZER-12.28%211 902
NOVARTIS21.74%208 547